2023
DOI: 10.3390/jcdd10060238
|View full text |Cite
|
Sign up to set email alerts
|

Cardioneuroablation Using Epicardial Pulsed Field Ablation for the Treatment of Atrial Fibrillation

Abstract: Atrial fibrillation (AF) is the most common cardiac arrhythmia affecting millions of people worldwide. The cardiac autonomic nervous system (ANS) is widely recognized as playing a key role in both the initiation and propagation of AF. This paper reviews the background and development of a unique cardioneuroablation technique for the modulation of the cardiac ANS as a potential treatment for AF. The treatment uses pulsed electric field energy to selectively electroporate ANS structures on the epicardial surface… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
4

Relationship

1
3

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 126 publications
0
2
0
Order By: Relevance
“…The main locations of the GPs include the following: the superior paraseptal ganglionated plexus (SPSGP, located in the upper area of the right atrium, medial to the outlet of the superior vena cava and lateral to the aortic root) which is the final common pathway of the right vagus that innervates the sinus node; the aorta-superior vena cava ganglionated plexus (Ao-SVC GP), anterior to the previous one; the inferior paraseptal ganglionated plexus (IPSGP, located in the posteroinferior area of the right interatrial septum, near the proximal coronary sinus, and around its ostium) which is the final common pathway of the left vagus that innervates the AV node; the left superior ganglionated plexus (LSGP); the left lateral ganglionated plexus (LLGP), also called GP of Marshall's ligament; right and left inferior ganglionated plexuses (RIGP and LIGP), sometimes identified as oblique sinus GP (OSGP) (1,(5)(6)(7)(8)(9)(10)(11).…”
Section: Discussionmentioning
confidence: 99%
“…The main locations of the GPs include the following: the superior paraseptal ganglionated plexus (SPSGP, located in the upper area of the right atrium, medial to the outlet of the superior vena cava and lateral to the aortic root) which is the final common pathway of the right vagus that innervates the sinus node; the aorta-superior vena cava ganglionated plexus (Ao-SVC GP), anterior to the previous one; the inferior paraseptal ganglionated plexus (IPSGP, located in the posteroinferior area of the right interatrial septum, near the proximal coronary sinus, and around its ostium) which is the final common pathway of the left vagus that innervates the AV node; the left superior ganglionated plexus (LSGP); the left lateral ganglionated plexus (LLGP), also called GP of Marshall's ligament; right and left inferior ganglionated plexuses (RIGP and LIGP), sometimes identified as oblique sinus GP (OSGP) (1,(5)(6)(7)(8)(9)(10)(11).…”
Section: Discussionmentioning
confidence: 99%
“…Потенциальным преимуществом этой методики в сравнении с традиционными методами (радиочастотной, лазерной аблацией, криоаблацией) является отсутствие серьезных термических повреждений прилежащих структур, прежде всего -пищевода и диафрагмального нерва. В недавно проведенном исследовании изучалось влияние электропорации на длительность ЭРП предсердий в качестве метода повреждения ГС предсердий в хроническом эксперименте [24]. Измерение ЭРП проводилось до и после аблации при стимуляции из области устья коронарного синуса.…”
Section: рис 7 коагуляционный некроз нервного ганглия в зоне аблации ...unclassified
“…The absence of such damage with endocardial PFA may, in part, explain the ceiling in efficacy outcomes. A technique for epicardial PFA of GPs is currently in development [18]; the safety and feasibility of this approach has already been demonstrated preclinically [19] and clinically [20] in open-chest surgical settings. Figure 1 shows the GP sites targeted in these studies, using two purposedesigned catheters and a pulsed field generator (AtriAN Medical Ltd., Galway, Ireland).…”
Section: Introductionmentioning
confidence: 99%